A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia Read more
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma Read more
Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma Read more
Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations Read more
A Randomized, Multicenter, Phase 2 Study Of DSP-7888 Dosing Emulsion In Combination With Bevacizumab Versus Bevacizumab Alone In Patients With Recurrent Or Progressive Glioblastoma Following Initial Therapy Read more
Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME) Read more
A Multicenter, Open-Label Study With A Randomized Control Arm Of The Efficacy, Safety, And Pharmacokinetics Of Intravenously Infused Berubicin In Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure Of Standard First Line Therapy Read more
